ArticleIntestinal research2024

Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.

Taku Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.